○Aki Ito^1,2, Yoichiro Isohama² (1. KISTEC, 2. Grad. Sch. Pharm. Sci., Tokyo Univ. of Science)

○Takeshi Kotake¹, Shimizu Saki¹, Inoue Tomomi¹, Ishiwata Syunji¹, Higuchi Yumi², Arai Kori², Katakami Tomohiro², Hoshi Hisae², Hoshino Keiji², Nishibe Kumiko², Masuda Kurumi², Myotoiwa Hiroaki², Narita Masago², Hattori Syo², Usui Takashi², Knagawa Sugayo², Nakahara Keisuke², Murauchi Tomoshi², Miyako Kazuhiko² (1. Div. of Clin. Phar. Med. Phar. & Therap., Kindai Univ., 2. FRONTIER Co.,Ltd.)

○Kento Arakawa¹, Shinichi Watanabe², Naoko Hayashi^1,3, Hiroki Iwata^1,3, Noriko Kobayashi^1,3, Kazuko Fujimoto¹, Katsunori Yamaura^1,3 (1. Keio Univ Faculty Pharm, 2. Teikyo Heisei Univ Pharm, 3. Keio Univ Commun Pharm)

○Ichiro Arai¹, Chika Uehara², Masayo Taira², Osami Takeda², Yoshimasa Nagashima², Masayuki Honda² (1. Dep. Kampo Pharm. Sci., Nihon Pharm. Univ., 2. Enlightenment outreach team, Japan Kampo Medicines Manufacturing Association)

○Keiko Konomura¹ (1. Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health)

○Mikie Yamato¹, Sumio Matzno², Hirohisa Doi¹, Ken-ichi Chonan¹ (1. Fac. Pharm., Showa Pharm Univ., 2. Fac. Pharm., Kindai Univ.)